Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Abstract：This retrospective analysis evaluated the efficacy and safety of Telitacicept in 10 patients with glomerulonephritis over a mean follow-up of two years. Treatment with Telitacicept was associated with a significant reduction in proteinuria, which decreased by 48.5% at 2 months and 72.5% at 5 months. A proteinuria reduction of more than 40% was achieved in half of the patients. Renal function, assessed by eGFR, remained stable throughout the observation period. Adverse events were generally mild, with rash being the most common (40%). These findings suggest that Telitacicept is a promising treatment option for glomerulonephritis, offering substantial antiproteinuric effects without compromising renal function.
Document:Observation on the Efficacy of Telitacicept in Treating 10 Cases of Glomerulonephritis
Objective: To observe the efficacy and safety of Telitacicept in treating patients with glomerulonephritis.
Methods: This study retrospectively reviewed 10 patients with glomerulonephritis who were treated with Telitacicept following renal biopsy at our hospital. All patients were followed for a period of two years
Baseline characteristics: including age, gender, body mass index (BMI), comorbidities (e.g., hypertension and diabetes), and renal pathological findings.Clinical and laboratory parameters: assessed at baseline and during each follow-up visit. These included blood pressure, proteinuria, urinary red blood cell count, serum albumin, serum creatinine, and estimated glomerular filtration rate (eGFR).Concomitant medications: use of glucocorticoids, other immunosuppressive agents, renin–angiotensin–aldosterone system inhibitors (RAASi), and SGLT2 inhibitors. The initial dosage and any subsequent adjustments of Telitacicept were also documented.Adverse events: all observed or patient-reported adverse reactions were recorded throughout the treatment and follow-up period.
Results:
1)The study cohort comprised 10 patients, including 8 cases of IgA nephropathy, 1 case of Henoch-Schönlein purpura nephritis, and 1 case of mesangial proliferative glomerulonephritis. The mean age was 45.1 years, 50% of the patients were male, and the mean BMI was 26.7 kg/m². At baseline, median proteinuria was 2.0 [IQR 1.0–3.9] g/d, and median eGFR was 84.6 [IQR 44.8–117.8] mL/min/1.73 m². All patients (100%) initially received Telitacicept 160 mg weekly. Concomitant medications included hormone therapy (60.0%), mycophenolate mofetil (MMF, 20.0%), hydroxychloroquine (30.0%), renin-angiotensin system inhibitors (RASI, 40.0%), and SGLT-2 inhibitors (20.0%). No patient received Tripterygium wilfordii.
2)Telitacicept medication and dose reduction
A significant reduction in proteinuria was observed from the 2-month follow-up onward. At 2 months, proteinuria decreased from a median of 1.5 [IQR 0.7–2.1] g/day to 0.7 [0.3–1.3] g/day, representing a median reduction of 48.5% [IQR 10.0–58.5]. By 5 months, among the 4 patients with available data, proteinuria declined from 1.3 [0.8–1.9] g/day to 0.3 [0.1–0.6] g/day, corresponding to a median reduction of 72.5% [57.8–83.8]. One patient assessed at 14 months exhibited a decrease in proteinuria from 0.38 g/day to 0.11 g/day (71.0% reduction). eGFR remained stable throughout the study, with no significant differences between baseline and follow-up visits (baseline: 84.6 [44.8–117.8] mL/min/1.73m²; 2 months: 83.0 [45.2–101.1] mL/min/1.73m²; 5 months: 85.7 [68.6–94.4] mL/min/1.73m²).
Over the entire treatment period, the median absolute reduction in proteinuria was 0.5 [0.1–1.0] g/day, equivalent to a median relative reduction of 44.0% [10.0–73.6]. Half of the patients (50.0%) achieved a proteinuria reduction exceeding 40%. Moreover, proteinuria was reduced to below 0.5 g/day in 40% of patients and to below 1.0 g/day in 50% of patients.
4 patients experienced local skin redness at the injection site; 3 patients developed abdominal rash; 1 patient developed a rash on the upper limb.
Conclusion:
This retrospective study demonstrates that Telitacicept significantly reduces proteinuria in patients with glomerulonephritis, with clinically meaningful reductions observed as early as 2 months after treatment initiation and further improvement over time. Renal function remained stable throughout the 2-year follow-up period, indicating no adverse impact on eGFR. Telitacicept exhibited a favorable safety profile, characterized primarily by mild injection-site reactions and rash, with no serious adverse events reported. These findings support Telitacicept as a promising and well-tolerated therapeutic option for the management of glomerulonephritis.
